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Mycoplasmas may colonize tumor tissue in patients. The cytostatic activity of gemcitabine was
dramatically decreased in Mycoplasma hyorhinis-infected tumor cell cultures compared with
non-infected tumor cell cultures. This mycoplasma-driven drug deamination could be prevented
by exogenous administration of the cytidine deaminase (CDA) inhibitor tetrahydrouridine, but also
by the natural nucleosides or by a purine nucleoside phosphorylase inhibitor. The M. hyorhinis-
encoded CDAHyor gene was cloned, expressed as a recombinant protein and purified. CDAHyor
was found to be more catalytically active than its human equivalent and efficiently deaminates
(inactivates) cytosine-based anticancer drugs. CDAHyor expression at the tumor site may result in
selective drug inactivation and suboptimal therapeutic efficiency.
 2015 The Authors. Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies. This
is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).1. Introduction If this phenomenon can be broadly confirmed and sinceMycoplasmas are considered to be the smallest self-replicating
organisms, both in dimension and genome size [1]. They often lack
genes that are crucial for different synthetic pathways, including
the de novo synthesis of purine and pyrimidine bases [2,3].
Therefore mycoplasmas rely on their host tissue from which they
scavenge and recycle DNA/RNA precursors using various
nucleo(s)(t)ide transporters and salvage enzymes [2,4,5].
Recently, we and others showed that certain catabolic mycoplasma
enzymes (i.e. pyrimidine nucleoside phosphorylase, purine
nucleoside phosphorylase and cytidine deaminase) interfere with
the biological (i.e. cytostatic and antiviral) activity of different
therapeutic nucleoside analogues (NAs) by producing less active
or inactive drug metabolites. This was demonstrated for both
pyrimidine- and purine-derived antimetabolites including
gemcitabine, floxuridine, trifluridine, cladribine, and others [6–10].
There have been several reports that mycoplasmas have been
shown to preferentially colonize tumor tissue in patients [11–20].nucleoside-derived drugs are established cornerstones in the
chemotherapy of several cancers [21], the presence of such
prokaryotes in the tumor microenvironment may be a confounding
factor for the efficiency of anticancer nucleoside analogues and of
importance for optimization of nucleoside-based cancer treatment
[22,23].
Recently, we reported efficient CDA-catalyzed deamination of
gemcitabine (20,20-difluoro-20-deoxycytidine; dFdC) resulting in a
dramatically decreased cytostatic activity (up to 60-fold) of this
drug in differentMycoplasma hyorhinis-infected tumor cell cultures
[10]. Similarly, the response of M. hyorhinis-infected tumor xeno-
grafts in mice to gemcitabine treatment was significantly lower
compared with uninfected control tumors [10]. The biological
function of CDA is to catalyze the irreversible deamination of the
natural pyrimidine nucleosides cytidine (Cyd) and
20-deoxycytidine (dCyd) to uridine (Urd) and 20-deoxyuridine
(dUrd), respectively [24]. However, several clinical anticancer
(d)Cyd analogues, including gemcitabine and cytarabine (cytosine
arabinoside; ara-Cyd) (Fig. 1), can be catabolized by (cellular) drug
deamination producing the corresponding, less active,
(20-deoxy)uridine metabolites. These molecules therefore show a
decreased cytostatic activity in CDA-overexpressing tumor cells
[25,26]. In the present study we biochemically and kinetically
characterizedM. hyorhinis-encoded CDA and report on a surprising
interaction betweenmycoplasma CDA and purine nucleoside phos-
phorylase (PNP) activity in mycoplasma-infected tumor cells.
Fig. 1. Molecular structure of the (20-deoxy)cytidine analogues gemcitabine (A) and
cytarabine (B).
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2.1. Chemicals
Nucleosides, nucleoside analogues and inorganic agents were
purchased from Sigma–Aldrich (St-Louis, MO) unless stated differ-
ently. Gemcitabine (20,20-difluoro-20-deoxycytidine; dFdC) was
purchased from Carbosynth (Berkshire, UK). Radioactive
[5-3H]-gemcitabine ([5-3H]-dFdC) (radiospecificity: 12 Ci/mmol)
was obtained from Moravek Biochemicals Inc. (Brea, CA).
Immucillin-H (Imm-H) was kindly provided by Dr. V. Schramm
(Albert Einstein College of Medicine, Bronx, NY).
2.2. Cell cultures
Human breast carcinoma MDA-MB-231 cells and M. hyorhinis
were obtained from the American Tissue Culture Collection
(Rockville, MD). Human breast carcinoma MCF-7 cells were
kindly provided by Prof. G.J. Peters (Amsterdam, The
Netherlands). Cells were infected with M. hyorhinis and after
two or more passages (to avoid bias by the initial inoculum)
successful infection was confirmed using the MycoAlert™
mycoplasma detection kit (Lonza, Basel, Switzerland). Although
this assay is only semi-quantitative, a maximal infection was
observed three to four days after subculturing the
mycoplasma-exposed cells. Chronically M. hyorhinis-infected
tumor cells are further referred to as MDA-MB-231.Hyor and
MCF-7.Hyor. All cells were maintained in Dulbecco’s modified
Eagle medium (Invitrogen, Carlsbad, CA) supplemented with
10% foetal bovine serum (Integro, Dieren, The Netherlands),
10 mM HEPES and 1 mM sodium pyruvate (Invitrogen) and grown
at 37 C in a humidified CO2-controlled incubator.
2.3. Biological assays
The cytostatic activity of dFdC (gemcitabine) was compared in
mycoplasma-infected and uninfected tumor cells. MDA-MB-231
and MDA-MB-231.Hyor cells were seeded in 48-well plates
(Nunc™, Roskilde, Denmark) at 10,000 cells/well. After 24 h, an
equal volume of fresh medium containing gemcitabine [in the
presence or absence of natural purine nucleosides (100 lM) or
the PNP inhibitor Imm-H (10 lM)] was added. Three days later
(to ensure sufficient cell-proliferation and mycoplasma growth),
cells were trypsinized and counted in a Coulter counter (Analis,
Suarlée, Belgium). The 50% inhibitory concentration (IC50) was
defined as the compound concentration required to reduce tumor
cell proliferation by 50%.2.4. Gemcitabine stability in the supernatant of mycoplasma-infected
and uninfected cell cultures
The stability of gemcitabine in spent cell-free but
mycoplasma-containing culture medium of confluent
MDA-MB-231, MDA-MB-231.Hyor, MCF-7 and MCF-7.Hyor tumor
cells was evaluated. Tumor cells were seeded in 75 cm2 culture
flasks (TTP, Trasadingen, Switzerland). After five days, supernatant
was withdrawn and cleared by centrifugation at 300g for 6 min to
remove (debris of) the tumor cells. Reactions were performed in a
final volume of 300 lL containing dFdC (5 lM), [5-3H]dFdC (1 lCi),
different concentrations of thymidine (dThd), uridine (Urd), adeno-
sine (Ado) or inosine (Ino) and 240 lL spent culture medium.
Samples were incubated at 37 C and after 60 min incubation,
100 lL was withdrawn and ice-cold MeOH was added to a final
concentration of 66% MeOH to terminate the enzymatic reactions
and to precipitate (remove) macromolecules such as DNA, RNA
and proteins. Samples were kept on ice for 10 min and cleared by
centrifugation at 16,000g for 15 min. The supernatants were with-
drawn and analyzed on a reverse phase RP-8 column (Merck,
Darmstadt, Germany) using HPLC (Alliance 2690, Waters, Milford,
MA). The following gradient (further referred to as gradient A)
was used: 10 min linear gradient of 100% buffer A [50 mM
NaH2PO4 (Acros Organics, Geel, Belgium); 5 mM heptane sulfonic
acid; pH 3.2] to 98% buffer A + 2% acetonitrile (BioSolve BV,
Valkenswaard, the Netherlands); 10 min linear gradient to 90%
buffer A + 10% acetonitrile; 5 min linear gradient to 75% buffer
A + 25% acetonitrile; 5 min linear gradient to 100% buffer A fol-
lowed by 10 min equilibration at 100% buffer A. Fractions of 1 mL
were collected, transferred to 9 mL OptiPhase HiSafe 3 and
radioactivity was counted in a liquid scintillation analyzer.
2.5. Purification of M. hyorhinis CDA (CDAHyor)
A codon-optimized DNA sequence encoding the M. hyorhinis
cytidine deaminase (CDAHyor) was synthetically assembled
between the EcoRI and NotI restriction sites of a pIDTsmart vector
(Integrated DNA technologies, Coralville, IO). The fragment was
subsequently subcloned between the EcoRI and NotI sites of the
pGEX-5X-1 bacterial expression vector (Amersham Pharmacia
Biotech, Uppsala, Sweden) and CDAHyor was expressed in
Escherichia coli as a GST-fusion protein (hereafter referred to as
CDAHyor) according to a procedure previously described by
Liekens et al. [27]. SDS–PAGE revealed that the protein was of
expected size (38–40 kDa) and purity (P95%) (Fig. 2). Since
E. coli CDA consists of 294 amino acids, it would be characterized
by a molecular weight of around 31 kDa [28]. Therefore, the con-
taminating protein bands shown in Fig. 2 are not likely related to
E. coli-encoded CDA.
2.6. Enzyme assays
2.6.1. Determination of the substrate specificity of CDAHyor and
CDAHuman
To study the deamination of different nucleosides and nucle-
oside analogues by CDAHyor and CDAHuman (ProSpec, Rehovot,
Israel) different potential substrates (100 lM) were exposed to
both enzymes (80 nM CDAHyor or 27 nM CDAHuman) and incubated
at 37 C in PBS in a total volume of 300 lL. At different time points,
100 lL-fractions were withdrawn and the reaction was terminated
by heat-inactivation of the enzyme at 95 C for 3 min. Next, the
samples were rapidly cooled on ice for 15 min and cleared by
centrifugation at 16,000g for 15 min. Nucleosides were separated
on a reverse phase RP-8 column (Merck) and quantified by HPLC
analysis. For each product UV-based detection was performed at
the specific wavelength of optimal absorption.
Fig. 2. Purity evaluation of the CDAHyor-GST fusion protein. Three different
concentrations (i.e. 10, 1 and 0.1 lg) of the purified enzyme preparation were
analyzed using SDS–PAGE. Proteins were stained using Bio-Safe™ Coomassie G-250
Stain (Bio-Rad Laboratories, CA, USA).
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(20-deoxy)uridine [(d)Urd] was performed by HPLC using linear
gradient B [from 100% buffer A and 2% acetonitrile to 80% buffer
A and 20% acetonitrile] as follows: 5 min 100% buffer A; 5 min lin-
ear gradient to 80% buffer A + 20% acetonitrile; 5 min linear gradi-
ent to 100% buffer A followed by 5 min equilibration at 100% buffer
A. Samples containing dFdC, ara-Cyd, 5-aza-20-deoxycytidine,
5-aza-cytidine, 20,30-dideoxycytidine (ddC) or 20,30-dideoxy-30-thi
acytidine (3TC) were analyzed by HPLC using linear gradient A as
described above.
2.6.2. Kinetic assays
Kinetic studies were performed for the deamination of different
substrates [Cyd, dCyd, dFdC and ara-Cyd] by CDAHyor and
CDAHuman. Deaminationwas studied at varying substrate concentra-
tions ranging from 100 lM to 45 mM in a reaction containing
4 nM CDAHyor or 11 nM CDAHuman incubated in PBS at 37 C for
10 min. Samples were processed and analyzed by HPLC
as described above. Kinetic parameters (KM and kcat) were deter-
mined by means of non-linear regression analysis (using GraphPad
Prism5) and the ratio kcat/KM (catalytic efficiency) was calculated.
3. Results
3.1. Deamination of gemcitabine by mycoplasma CDA can be
prevented in the presence of exogenous natural purine and pyrimidine
nucleosides
The cytostatic activity of gemcitabine (dFdC) was decreased by
36 fold in M. hyorhinis-infected MDA-MB-231 breast cancer cellcultures compared with uninfected control tumor cells (Table 1).
This could be prevented by co-administration of 250 lM of the
cytidine deaminase inhibitor tetrahydrouridine (THU), but also
by natural purine nucleosides (i.e. Ado, Ino or Guo) as well as by
Immucillin-H (Imm-H), a potent inhibitor of mycoplasma PNP
(Table 1).
Since THU could efficiently restore the cytostatic activity of dFdC
in the presence of M. hyorhinis in the tumor cell culture medium,
the stability of radiolabeled dFdC ([5-3H]dFdC) was studied in the
tumor cell-free (but mycoplasma-containing) culture medium of
M. hyorhinis-infected MDA-MB-231 (Fig. 3A) and MCF-7 (Fig. 3B)
breast cancer cells. A pronounced inhibition of [5-3H]-dFdC deami-
nation (i.e. decreased formation of the inactive metabolite
[5-3H]-dFdU) by 1 mM THU could be observed [10], but also, a
dose-dependent inhibition of [5-3H]dFdC deamination by the
exogenous supply of natural pyrimidine (i.e. dThd and Urd) or pur-
ine (i.e. Ado and Ino) nucleosides was observed in the spent tumor
cell culture medium (Fig. 3). Also, [5-3H]-dFdU formation could be
inhibited by exogenous administration of other natural nucleosides
such as Guo, dAdo, dIno or dGuo (data not shown).
3.2. Substrate specificity of human- and mycoplasma-encoded CDA
The substrate specificity of recombinant M. hyorhinis CDA
(CDAHyor) was studied and compared with CDAHuman. Both
enzymes catalyzed the deamination of the natural pyrimidine
nucleosides Cyd and dCyd, and the well-known anticancer drugs
dFdC and ara-Cyd. Deamination of 5-aza-20-deoxycytidine (decita-
bine) and 5-aza-cytidine (vidaza), both used for the treatment of
myelodysplastic syndromes [29], was also observed in the pres-
ence of CDAHyor but could not be demonstrated for CDAHuman.
The antiviral (i.e. HIV) drugs 20,30-dideoxycytidine (ddC; zal-
citabine) and 20,30-dideoxy-30-thiacytidine (3TC; lamivudine) were
found to be insensitive to deamination by both human and myco-
plasma CDA.
3.3. Kinetics of human- and mycoplasma-encoded CDA
The kinetic parameters (KM and kcat) for CDAHyor- and
CDAHuman-catalyzed deamination of Cyd, dCyd, dFdC and ara-Cyd
were determined. Relatively high KM values (ranging from high
micromolar to low millimolar concentrations) were observed for
both enzymes. CDAHyor typically displayed higher KM values
compared with CDAHuman (Tables 2 and 3 and Fig. 4). However, the
catalytic efficiency (calculated as kcat/KM) of CDAHyor-catalyzed
reactions was 2–4 fold higher compared with CDAHuman (Tables 2
and 3).
Interestingly, deamination of both dFdC and ara-Cyd by
CDAHyor, but not by CDAHuman, was characterized by a second KM
at very high (and presumably biologically irrelevant) concentra-
tions. However, precise values could not be determined due to
insolubility of the highest drug concentrations (45 mM in the
reaction mixture) tested. The calculated KM for dFdC and ara-Cyd
as represented in Table 2 was therefore based on the measure-
ments obtained when using up to 30 mM substrate.
Measurements obtained using higher concentrations were
excluded from the non-linear regression analysis but are still dis-
played in Fig. 4E (for dFdC) and Fig. 4G (for ara-Cyd). For these
above-mentioned reasons, we preferred not to draw a curve line
fitting the experimental data points in Fig. 4E and G.
4. Discussion
Recent studies have focused on the role of commensal prokary-
otes in the efficiency of chemotherapeutic cancer treatment. For
example, an intact intestinal microbiome seems to be essential
Table 1
Cytostatic activity of gemcitabine (dFdC) in MDA-MB-231 and MDA-MB-231. Hyor cells in the absence/presence of the selective CDA inhibitor tetrahydrouridine, natural purine
nucleosides or the selective purine nucleoside phosphorylase inhibitor Immucillin-H (Imm-H). Results are the mean ± S.D. of at least two independent experiments.
IC50a value of dFdC (lM)
As such +THU (250 lM) +Ado (100 lM) +Ino (100 lM) +Guo (100 lM) +Imm-H (10 lM)
MDA-MB-231 0.0042 ± 0.00041 0.004 ± 0.0003 0.0031 ± 0.0014 0.0037 ± 0.00076 0.0042 ± 0.0012 0.0037 ± 0.00076
MDA-MB-231.Hyor 0.15 ± 0.016 0.004 ± 0.0001 0.0096 ± 0.0049 0.0099 ± 0.0042 0.025 ± 0.0089 0.0051 ± 0.0021
Fold difference 36 1 3 3 6 1.5
a 50% Inhibitory concentration or compound concentration required to inhibit tumor cell proliferation by 50%.
Fig. 3. Inhibition of mycoplasma-associated [5-3H]dFdU formation by natural nucleosides. Formation of [5-3H]dFdU from [5-3H]dFdC in the tumor cell-free supernatant of
mycoplasma-infected and control MDA.MB.231 (A) and MCF-7 (B) breast cancer cell cultures in the presence/absence of different concentrations of pyrimidine (dThd and
Urd) and purine (Ado and Ino) nucleosides. The data are the mean of at least two independent experiments (±S.E.M.).
Table 2
Kinetic parameters of CDAHyor. The KM and kcat values ± S.E.M. for the natural
substrates of CDAHyor and for gemcitabine and cytarabine were determined using
nonlinear regression analysis (using GraphPad Prism 5) from data obtained in at least
two independent experiments.
KM (lM) kcat (s1) kcat/KM (s lM)1
Cytidine 1898 ± 163 171 ± 5 0.090
20-Deoxycytidine 2586 ± 114 127 ± 2 0.049
dFdC 9064 ± 1487 105 ± 7 0.012
ara-Cyd 6172 ± 2336 119 ± 13 0.019
Table 3
Kinetic parameters of CDAHuman. The KM and kcat values ± S.E.M. for the natural
substrates of CDAHuman and for gemcitabine and cytarabine were determined using
nonlinear regression analysis (using GraphPad Prism 5) from data obtained in at least
two independent experiments.
KM (lM) kcat (s1) kcat/KM (s lM)1
Cytidine 811 ± 181 17 ± 1 0.021
20-Deoxycytidine 373 ± 138 7.8 ± 0.64 0.021
dFdC 3080 ± 598 14 ± 0.91 0.004
ara-Cyd 2853 ± 741 15 ± 1.3 0.005
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doxorubicin- or cyclophosphamide-based cancer chemotherapy
[30,31]. Conversely, the presence of some prokaryotes (e.g.
mycoplasmas) in the tumor microenvironment may negatively
influence the outcome of nucleoside-based treatment of cancer
[23]. A thorough understanding of the implications of the (tumor)
microbiome on cancer chemotherapy may ultimately lead to a
more optimal treatment strategy (e.g. by combination therapywith antibiotics or specific prokaryotic enzyme inhibitors) and
may also attenuate adverse side-effects.
In this report, we investigated the catabolic action of
mycoplasma-encoded cytidine deaminase against the anticancer
nucleoside analogues gemcitabine and cytarabine. To the best of
our knowledge, this study is the first to describe the biochemical
properties of the CDA encoded by M. hyorhinis, a commensal that
has been repeatedly reported to preferentially associate with
tumor tissue in patients. We found that CDAHyor does not only
catalyze the deamination of natural cytidine and 20-deoxycytidine
but also of several clinical nucleoside antimetabolites, including
gemcitabine and cytarabine. The efficiency of substrate conversion
catalyzed by CDAHyor was consistently higher compared with the
human equivalent enzyme. In addition, we observed deamination
of 5-aza-20-deoxycytidine and 5-aza-cytidine by CDAHyor but not
by CDAHuman under similar experimental conditions. Based on
these observations it could be expected that pronounced inactiva-
tion of different anticancer (20deoxy)cytidine analogues may occur
in mycoplasma-infected tumors leading to reduced efficacy.
Indeed, expression of CDAHyor explains the predominantly high
levels of (the poorly cytostatic) [5-3H]dFdU derived from radiola-
beled gemcitabine in the culture medium of
mycoplasma-infected tumor cell cultures and, as a result, the con-
sequently decreased cytostatic activity of this drug in these tumor
cell cultures (Table 1) and xenografts in mice [10]. Somewhat sur-
prisingly, we found that the stability and biological (cytostatic)
activity of gemcitabine in mycoplasma-infected tumor cell cultures
could be restored by (i) the co-administration of natural pyrim-
idine (i.e. dThd and Urd) and purine (i.e. Ado, Ino and Guo) nucle-
osides and (ii) administration of a specific PNP inhibitor.
Interestingly, inhibition of Escherichia coli and human CDA by dif-
ferent nucleosides [i.e. dThd, (d)Urd, (d)Ado and (d)Guo] has been
Fig. 4. Kinetic analysis of CDAHyor- and CDAHuman-catalyzed deamination of natural nucleosides and nucleoside analogues Deamination of different concentrations of Cyd (A
and B), dCyd (C and D), dFdC (E and F) and ara-Cyd (G and H) by CDAHyor (A, C, E and G) or CDAHuman (B, D, F and H). The data are the mean of at least two independent
experiments (±S.E.M.).
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M. hyorhinis PNP is responsible for the catabolism of different
purine nucleoside analogues, including cladribine and fludarabine
[9]. It can be hypothesized that M. hyorhinis-related PNP activity
may also indirectly contribute to the deamination of cytidine
analogues by depletion of those intracellular purine nucleosides
that seem to act as natural inhibitors of CDAHyor. Exogenous
administration of these natural nucleosides may then restore the
depleted purine nucleoside pools and, as a result, also the
cytostatic potential of gemcitabine. This hypothesis would then
also explain the rescuing cytostatic activity of gemcitabine by
Immucillin-H, a potent and selective PNP inhibitor. Earlier, wereported a similar concerted action between CDAHyor and the
M. hyorhinis-encoded pyrimidine nucleoside phosphorylase which
catabolizes dThd, Urd and dUrd [10]. However, when exposing
purified CDAHyor to different substrates (Cyd, dCyd or dFdC) in
the presence of natural purine nucleosides or dThd, we could not
observe decreased deamination (data not shown). It is therefore
unlikely that the observed rescue of gemcitabine is due to a direct
interaction of CDAHyor with purine nucleosides or dThd. Although
inhibition of CDA by (d)Urd may be explained by end-product
feedback inhibition, the mechanism of CDAHyor-inhibition by
dThd and the purine nucleosides remains unclear. In this respect,
it cannot be excluded that interaction (i.e. inhibition) of CDA can
J. Vande Voorde et al. / FEBS Open Bio 5 (2015) 634–639 639be attributed to the mono-, di- or triphosphorylated derivatives of
the natural nucleosides that were found inhibitory to
CDAHyor-catalyzed deamination of gemcitabine. Alternatively, the
natural nucleosides may compete for uptake with dFdC by
M. hyorhinis and therefore lower the amount of drug to be
deaminated intracellularly by the mycoplasma.
In conclusion, we have kinetically characterized theM. hyorhinis-
encoded CDA and found it more catalytically efficient than
human CDA. It deaminates (inactivates) anticancer drugs such as
gemcitabine and cytarabine, but also 5-aza-(20-deoxy)cytidine. Its
deaminating action may negatively affect the cytostatic activity
of anti-cancer drugs such as gemcitabine, but could be annihilated
by co-administration of natural nucleosides or a specific PNP
inhibitor.
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